Modality
Multispecific
MOA
BCMA ADC
Target
IL-17A
Pathway
Autophagy
SLEBCC
Development Pipeline
Preclinical
~Aug 2014
→ ~Nov 2015
Phase 1
~Feb 2016
→ ~May 2017
Phase 2
~Aug 2017
→ ~Nov 2018
Phase 3
~Feb 2019
→ ~May 2020
NDA/BLA
Aug 2020
→ Oct 2026
NDA/BLACurrent
NCT06137469
304 pts·BCC
2020-08→2026-10·Not yet recruiting
304 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-10-267mo awayPh3 Readout· BCC
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2026-10-26 · 7mo away
BCC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06137469 | NDA/BLA | BCC | Not yet recr... | 304 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| Tixatapinarof | Recursion | Approved | FGFR | |
| Terazumab | Recursion | Phase 3 | AHR |